Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.57% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTInvivyd, Inc.'s latest supported as-filed period reports revenue of $14.3M, 21.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.57% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -301.05% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 21.20% · CORE
Level · gp.fundamentals.operating_margin
Raw value -320.76% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 205.58% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 20.27% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 21.2%; Operating margin moved 19298 bp lower; Operating income decreased 204.2%.
3 evidence-backed componentsOperating income changed -204.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
IVVD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-380337SEC ↗4Sep 1, 2026Period Aug 30, 20260001193125-26-378862SEC ↗8-KSep 1, 2026Period Aug 30, 20260001193125-26-377493SEC ↗4Aug 18, 2026Period Aug 15, 20260001193125-26-355915SEC ↗4Aug 18, 2026Period Aug 15, 20260001193125-26-355914SEC ↗4Aug 18, 2026Period Aug 15, 20260001193125-26-355913SEC ↗4Aug 18, 2026Period Aug 15, 20260001193125-26-355912SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026Filed Sep 2, 2026 | Sheffield IanDirector | Grant Or AwardDirect | 100,000 | $0 | $0 | Form 4 ↗ |
| Aug 30, 2026Filed Sep 1, 2026 | Elia MarcChief Executive Officer | Grant Or AwardDirect | 10,700,000 | $0 | $0 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 18, 2026 | Lee Timothy EdwardChief Commercial Officer | Open Market SaleDirect | 18,425 | $1 | $15,530 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 18, 2026 | Lee Timothy EdwardChief Commercial Officer | Open Market SaleDirect | 22,355 | $1 | $16,140 | Form 4 ↗ |
| Aug 15, 2026Filed Aug 18, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +206.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Selling, general & administrative changed +77.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -202.8% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed -19298 basis points from the comparable as-filed period.
Cash & equivalents changed +358.6% from the comparable as-filed period.
Revenue changed +21.2% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-355911| Lee Timothy EdwardChief Commercial Officer |
| Option ExerciseDirect |
| 102,000 |
| — |
| — |
| Form 4 ↗ |
| Aug 15, 2026Filed Aug 18, 2026 | Lee Timothy EdwardChief Commercial Officer | Option ExerciseDirect | 102,000 | $0 | $0 | Form 4 ↗ |